Cache Test Div

BIOFLOW-V

Comparison of Ultrathin strut Orsiro® Bioresorbable Polymer DES to Xience Durable Polymer DES at 60 Months1

PRINCIPAL INVESTIGATOR OF THE FDA PIVOTAL BIOFLOW-V TRIAL PRESENTS 5-YEAR OUTCOMES

David E. Kandzari, MD, Atlanta, USA

Conclusions

• Orsiro ultrathin struts DES outperformed Xience at 1-year and sustained performance up to 5 years:                                                                                                                       
   • 20% lower Target Lesion Failure (p = 0.136)
   • 36% lower Target Vessel Myocardial Infarction (p = 0.021)
   • 23% lower Ischemia-Driven TLR (p = 0.223) 
   • 22% lower Cardiac Death/Myocardial Infarction (p = 0.121)                                                                                                                       
• Orsiro showed a 0.7% definite/probable stent thrombosis rate overall through 5 years: 64% lower compared to Xience (p=0.120)
   •83% lower late/very late definite/prob ST (p = 0.021)

Study design

Prospective, multi-center, 2:1 randomized controlled IDE trial to assess the safety and effectiveness of Orsiro in the treatment of patients with up to three de novo or restenotic lesions (standard PTCA only)

Endpoints

Primary Endpoints
Target Lesion Failure (TLF) at 12 months follow-up defined as the composite of:
• Cardiac Death
• Target Vessel-Myocardial Infarction (TV-MI)
• Ischemia-driven Target Lesion Revascularization

Secondary Endpoints
• Components of the primary endpoint
• MACE as a composite of all-cause death, MI or ischemia-driven TLR
• Target Vessel Failure (TVF) and individual TVF components
• Stent Thrombosis (all, definite, definite/probable, probable, possible ST)Δ

Orsiro_Flow_Chart
Patient characteristics4,5 Orsiro n = 884 Xience n = 450
Age, yrs* 64.5 ± 10.3 64.6 ± 10.7
Female 25.3% 27.1%
Hypertension 79.7% 80.5%
Diabetes 34.0% 37.0%
Stable Angina 48.4% 47.4%
Acute Coronary Syndrome◊ 51.4% 49.6%
Previous PCI 36.8% 33.0%
Previous CABG 7.1% 5.2%

Lesion characteristic4,5 Orsiro n = 1,051 Xience n = 561
Lesion length (mm)* 13.3 ± 7.6 13.2 ± 7.7
Bifurcation lesion 14.8% 15.0%
Calcification, moderate/severe 24.0% 26.7%
Lesion Class B2/C 72.6% 75.9%
Number of target lesion/patient*§ 1.2 ± 0.4 1.3 ± 0.5
Number of stents/patient*§ 1.3 ± 0.7 1.5 ± 0.9
Total stent length (mm)*§ 26.8 ± 14.7 29.5 ± 17.5
Reference vessel diameter (mm)* 2.59 ± 0.54 2.60 ± 0.58

Target-lesion characteristics as assessed by an independent angiographic core laboratory.


Δ According to Academic Research Consortium (ARC) criteria for acute, subacute, late, very late and cumulative stent thrombosis
* Data shown as mean ± SD
◊ Acute coronary syndrome defined as subjects with unstable angina or any elevated cardiac enzymes at baseline (any pre-procedure CK, CK-MB or troponin out of normal range)
§ There were no statistically significant differences (P < 0.05) between groups except for variable denoted by (§). Multivariable analysis of TLF, TV-MI and TLR confirmed no clinical, angiographic or procedural characteristic that differed between group was identified as a predictor of adverse outcome.

Presented information is based on unrounded values.

TLF out to 5 years1-5

Outcomes out to 5 years1-5

ST events out to 5 years1

Principal investigators

Dr. David Kandzari, Piedmont Heart Institute, Atlanta, US
Dr. Jacques Koolen, Catharina Ziekenhuis, Eindhoven, the Netherlands

PCI: Percutaneous Coronary Intervention, CABG: Coronary Artery Bypass Graft, DES: Drug Eluting Stent, PTCA: Percutaneous Transluminal Coronary Angioplasty, IDE: Investigational Device Exemption, DP-EES: Durable Polymer Everolimus-Eluting Stents.

*p-values for 60-month frequentist analysis

1. Kandzari D Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coronary Revascularization: Final 5-year Outcomes from the Randomized BIOFLOW V Trial. Presented at CRT 2022; 2. Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j. jcin.2020.02.019; 3. Kandzari D et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents. Journal of the American College of Cardiology. 2018 Dec 17;72(25):3287-97; 4. Kandzari D, et al. BIOFLOW-V: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions Science. Presentation at ESC 2017; 5. Kandzari D et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21; 390(10105):1843-1852.

Orsiro and Orsiro Mission are a trademarks or registered trademarks of the BIOTRONIK Group of Companies. Xience is a trademark or registered trademark of the Abbott Group of Companies. 

Presented information is based on unrounded values.

Do you want to further explore Orsiro's extensive clinical program?

CONTACT US